长链非编码RNA SERTAD1-1在结直肠癌中的表达及意义

目的 探讨长链非编码RNA-癌基因SEI1-1（lnc-SERTAD1-1）对结直肠癌增殖、迁移及预后的影响。方法 选取125例结直肠癌患者的标本,检测癌组织和癌旁正常组织中lnc-SERTAD1-1的表达水平,分析lnc-SERTAD1-1与临床病理特征的相关性,分析lnc-SERTAD1-1对结直肠癌预后的影响。检测正常人结肠组织细胞CCD-18Co与人结直肠癌细胞HCT15中lnc-SERTAD1-1的表达。慢病毒转染构建含有目的基因lnc-SERTAD1-1过表达的HCT15（HO）及含有空白载体质粒的HCT15（HOC）,检测其lnc-SERTAD1-1以及SERTAD1蛋白的表达,并检测lnc-SERTAD1-1对结直肠癌细胞增殖和迁移能力的影响。结果 与癌旁正常组织比较,lnc-SERTAD1-1在结直肠癌组织（0.002 198±0.000 499 vs. 0.002 998±0.000 392,P < 0.001）和癌细胞（0.000 123±0.000 010 vs. 0.000 182±0.000 012,P = 0.004）中呈低表达水平 ;其表达高低与结直肠癌患者的肿瘤部位、肿瘤大小及肿瘤的大体分型相关（P均< 0.05）。在125例结直肠癌患者中,lnc-SERTAD1-1高表达（≥0.000 970）是其术后总生存及无病生存的独立保护因素（总生存HR = 0.228,95% CI：0.107 ~ 0.485,P < 0.001;无病生存HR = 0.228,95% CI：0.103 ~ 0.506,P < 0.001）。体外实验显示lnc-SERTAD1-1表达上调能抑制结直肠癌细胞的增殖和迁移（P均< 0.05）。结论 lnc-SERTAD1-1通过抑制结直肠癌细胞的增殖和迁移发挥抑癌基因的作用,是结直肠癌重要的预后影响因素。

Expression and significance of lnc-RNA SERTAD1-1 in colorectal cancer

Objective To evaluate the effect of the long non-coding RNA（lncRNA）-SERTAD1-1 （lnc-SERTAD1-1） on the proliferation, migration and prognosis of colorectal cancer （CRC）. Methods A total of 125 samples were collected from CRC patients. The expression levels of lnc-SERTAD1-1 in the cancer tissues and adjacent normal tissues were measured. The correlation between lnc-SERTAD1-1 and clinicopathological characteristics was analyzed. The effect of lnc-SERTAD1-1 upon clinical prognosis of CRC patients was evaluated. The expression levels of lnc-SERTAD1-1 in normal human colon tissue cell CCD-18Co and human CRC cell line HCT15 were determined. HCT15 cells （HO） containing the overexpression of the target gene lnc-SERTAD1-1 and HCT15 cells （HOC） containing an empty vector plasmid were constructed by using lentiviral transfection. The expression levels of lnc-SERTAD1-1 and SERTAD1 protein were determined. The effect of lnc-SERTAD1-1 upon the proliferation and migration ability of CRC cells was assessed. Results Compared with adjacent normal tissues, lnc-SERTAD1-1 was lowly expressed in the CRC tissues and cancer cells （cancer tissues： 0.002 198±0.000 499 vs. 0.002 998±0.000 392,P < 0.001; cancer cells： 0.000 123±0.000 010 vs. 0.000 182±0.000 012, P < 0.004）. The expression level of lnc-SERTAD1-1 was significantly correlated with the location, size and general classification of the tumor in CRC patients （all P < 0.05）. Among 125 CRC patients, high expression of lnc-SERTAD1-1 （≥0.000 970） was an independent protective factor of the overall survival （OS） and disease-free survival （DFS） of CRC patients （HR = 0.228, 95%CI：0.107-0.485, P < 0.001 for OS; HR = 0.228, 95%CI：0.103-0.506, P < 0.001 for DFS）. In vitro experiment revealed that up-regulation of lnc-SERTAD1-1 expression significantly inhibited the proliferation and migration of CRC cells （both P < 0.05）. Conclusion lnc-SERTAD1-1 plays the role of tumor suppressor in CRC via suppressing cell proliferation and migration, which is a critical prognostic factor of CRC．